{"id":51182,"date":"2025-12-17T22:20:37","date_gmt":"2025-12-17T14:20:37","guid":{"rendered":"https:\/\/flcube.com\/?p=51182"},"modified":"2025-12-17T22:20:38","modified_gmt":"2025-12-17T14:20:38","slug":"kelun-biotech-settles-with-medilink-in-multi-million-dollar-adc-revenue-sharing-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51182","title":{"rendered":"Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal"},"content":{"rendered":"\n<p><strong>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/6990:HKG\">HKG: 6990<\/a>) announced a settlement agreement with <strong>Medilink Therapeutics<\/strong> resolving trade secret disputes and establishing <strong>revenue sharing<\/strong> for six ADC programs. Kelun-Biotech had filed criminal and civil complaints in 2024\u20112025; under the settlement, Medilink will share past and future licensing and sales revenues from <strong>YL201 (B7H3), YL202 (HER3), YL211 (cMet), YL212 (DLL3), YL221 (EGFR), and YL222 (PD\u2011L1)<\/strong> ADC assets.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-settlement-overview\">Settlement Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parties<\/th><th>Dispute History<\/th><th>Resolution<\/th><\/tr><\/thead><tbody><tr><td><strong>Kelun-Biotech (Plaintiff)<\/strong><\/td><td>Filed criminal complaint (2024) and civil lawsuits (2025)<\/td><td>Alleged trade secret infringement and harm to interests<\/td><\/tr><tr><td><strong>Medilink Therapeutics (Defendant)<\/strong><\/td><td>Counterparty in legal proceedings<\/td><td>Agreed to revenue sharing settlement<\/td><\/tr><tr><td><strong>Legal Status<\/strong><\/td><td>All disputes resolved<\/td><td>Settlement agreement terminates all active litigation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-revenue-sharing-terms\">Revenue Sharing Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Asset<\/th><th>Target<\/th><th>Revenue Share Scope<\/th><\/tr><\/thead><tbody><tr><td><strong>YL201<\/strong><\/td><td>B7H3<\/td><td>Past out\u2011licensing revenue + future sales<\/td><\/tr><tr><td><strong>YL202<\/strong><\/td><td>HER3<\/td><td>Past out\u2011licensing revenue + future sales<\/td><\/tr><tr><td><strong>YL211<\/strong><\/td><td>cMet<\/td><td>Past out\u2011licensing revenue + future sales<\/td><\/tr><tr><td><strong>YL212<\/strong><\/td><td>DLL3<\/td><td>Past out\u2011licensing revenue + future sales<\/td><\/tr><tr><td><strong>YL221<\/strong><\/td><td>EGFR<\/td><td>Past out\u2011licensing revenue + future sales<\/td><\/tr><tr><td><strong>YL222<\/strong><\/td><td>PD\u2011L1<\/td><td>Past out\u2011licensing revenue + future sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Financial Impact:<\/strong> Proportion of revenues undisclosed; estimated <strong>$50\u2011100\u202fmillion<\/strong> near\u2011term based on Medilink\u2019s recent licensing deals.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Kelun-Biotech:<\/strong> <strong>Settlement monetizes<\/strong> previously contested IP without further litigation risk; provides <strong>non\u2011dilutive revenue stream<\/strong> from six ADC programs; validates <strong>proprietary ADC platform<\/strong> and targeting strategy.<\/li>\n\n\n\n<li><strong>For Medilink:<\/strong> Resolves legal overhang; retains operational control while <strong>sharing economics<\/strong>; preserves ability to advance pipeline with partners (e.g., recent out\u2011licensing to global pharma).<\/li>\n\n\n\n<li><strong>For ADC Market:<\/strong> Demonstrates <strong>IP value<\/strong> in targeted oncology platforms; <strong>revenue\u2011sharing model<\/strong> may become template for similar disputes; <strong>six targets<\/strong> address <strong>$15\u202fbillion<\/strong> combined ADC market opportunity.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding revenue estimates, settlement enforceability, and market impact. Actual results may differ due to partner commercial performance, regulatory changes, or legal interpretation.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121601235_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025121601235_c.\"><\/object><a id=\"wp-block-file--media-04aaec96-f3c9-44b4-b7b1-23a56c60c963\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121601235_c.pdf\">2025121601235_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2025121601235_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-04aaec96-f3c9-44b4-b7b1-23a56c60c963\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced a settlement agreement with Medilink Therapeutics resolving&#8230;<\/p>\n","protected":false},"author":1,"featured_media":51185,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,971,1832,372],"class_list":["post-51182","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adc-xdc","tag-hkg-6990","tag-kelun-biotech-biopharmaceutical","tag-medilink-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced a settlement agreement with Medilink Therapeutics resolving trade secret disputes and establishing revenue sharing for six ADC programs. Kelun-Biotech had filed criminal and civil complaints in 2024\u20112025; under the settlement, Medilink will share past and future licensing and sales revenues from YL201 (B7H3), YL202 (HER3), YL211 (cMet), YL212 (DLL3), YL221 (EGFR), and YL222 (PD\u2011L1) ADC assets.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=51182\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal\" \/>\n<meta property=\"og:description\" content=\"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced a settlement agreement with Medilink Therapeutics resolving trade secret disputes and establishing revenue sharing for six ADC programs. Kelun-Biotech had filed criminal and civil complaints in 2024\u20112025; under the settlement, Medilink will share past and future licensing and sales revenues from YL201 (B7H3), YL202 (HER3), YL211 (cMet), YL212 (DLL3), YL221 (EGFR), and YL222 (PD\u2011L1) ADC assets.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=51182\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-17T14:20:37+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-17T14:20:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1706.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51182#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51182\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal\",\"datePublished\":\"2025-12-17T14:20:37+00:00\",\"dateModified\":\"2025-12-17T14:20:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51182\"},\"wordCount\":314,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51182#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1706.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"HKG: 6990\",\"Kelun-Biotech Biopharmaceutical\",\"MediLink Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51182#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51182\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=51182\",\"name\":\"Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51182#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51182#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1706.webp\",\"datePublished\":\"2025-12-17T14:20:37+00:00\",\"dateModified\":\"2025-12-17T14:20:38+00:00\",\"description\":\"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced a settlement agreement with Medilink Therapeutics resolving trade secret disputes and establishing revenue sharing for six ADC programs. Kelun-Biotech had filed criminal and civil complaints in 2024\u20112025; under the settlement, Medilink will share past and future licensing and sales revenues from YL201 (B7H3), YL202 (HER3), YL211 (cMet), YL212 (DLL3), YL221 (EGFR), and YL222 (PD\u2011L1) ADC assets.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51182#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51182\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51182#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1706.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1706.webp\",\"width\":1080,\"height\":608,\"caption\":\"Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51182#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced a settlement agreement with Medilink Therapeutics resolving trade secret disputes and establishing revenue sharing for six ADC programs. Kelun-Biotech had filed criminal and civil complaints in 2024\u20112025; under the settlement, Medilink will share past and future licensing and sales revenues from YL201 (B7H3), YL202 (HER3), YL211 (cMet), YL212 (DLL3), YL221 (EGFR), and YL222 (PD\u2011L1) ADC assets.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=51182","og_locale":"en_US","og_type":"article","og_title":"Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal","og_description":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced a settlement agreement with Medilink Therapeutics resolving trade secret disputes and establishing revenue sharing for six ADC programs. Kelun-Biotech had filed criminal and civil complaints in 2024\u20112025; under the settlement, Medilink will share past and future licensing and sales revenues from YL201 (B7H3), YL202 (HER3), YL211 (cMet), YL212 (DLL3), YL221 (EGFR), and YL222 (PD\u2011L1) ADC assets.","og_url":"https:\/\/flcube.com\/?p=51182","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-17T14:20:37+00:00","article_modified_time":"2025-12-17T14:20:38+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1706.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=51182#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=51182"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal","datePublished":"2025-12-17T14:20:37+00:00","dateModified":"2025-12-17T14:20:38+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=51182"},"wordCount":314,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=51182#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1706.webp","keywords":["ADC \/ XDC","HKG: 6990","Kelun-Biotech Biopharmaceutical","MediLink Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=51182#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=51182","url":"https:\/\/flcube.com\/?p=51182","name":"Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=51182#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=51182#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1706.webp","datePublished":"2025-12-17T14:20:37+00:00","dateModified":"2025-12-17T14:20:38+00:00","description":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced a settlement agreement with Medilink Therapeutics resolving trade secret disputes and establishing revenue sharing for six ADC programs. Kelun-Biotech had filed criminal and civil complaints in 2024\u20112025; under the settlement, Medilink will share past and future licensing and sales revenues from YL201 (B7H3), YL202 (HER3), YL211 (cMet), YL212 (DLL3), YL221 (EGFR), and YL222 (PD\u2011L1) ADC assets.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=51182#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=51182"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=51182#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1706.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1706.webp","width":1080,"height":608,"caption":"Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=51182#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Kelun-Biotech Settles with Medilink in Multi-Million Dollar ADC Revenue Sharing Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1706.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51182"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51182\/revisions"}],"predecessor-version":[{"id":51186,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51182\/revisions\/51186"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/51185"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}